<unk>  (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.<unk>  was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. In the United States,<unk>  is in Phase III clinical trials and the Food and Drug Administration has granted<unk>  Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema.<unk>  works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.
Delgocitinib
Abrocitinib
Baricitinib
Upadacitinib
Erdafitinib
Oclacitinib
Gilteritinib
Dacomitinib